EG632778 Activators
Glutamate rich 4 activators, or ERICH4 activators, encompass a range of compounds that interact with various aspects of the glutamatergic signaling system. These compounds have been selected based on their known or plausible effects on glutamate signaling or related pathways, which could influence the functional activity of ERICH4. The selected chemicals either directly activate glutamate receptors, modulate receptor sensitivity, or influence signaling pathways that are closely associated with glutamatergic neurotransmission. For instance, compounds like L-Glutamic acid, NMDA, AMPA, and Kainic acid serve as agonists for different types of glutamate receptors, which are central to excitatory neurotransmission in the brain. Their activation of these receptors can lead to a cascade of intracellular signaling events that would be expected to enhance the activity of proteins such as ERICH4, assuming they are involved in these signaling pathways.
Other compounds, such as D-Serine and S-Nitrosoglutathione, act as modulators of the glutamatergic system, either by serving as co-agonists or by releasing neuromodulators that affect neurotransmission, respectively. These actions can potentiate the signaling pathways that glutamate receptors are part of, potentially leading to increased activity of ERICH4.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
L-Glutamic Acid | 56-86-0 | sc-394004 sc-394004A | 10 g 100 g | $297.00 $577.00 | ||
As the primary excitatory neurotransmitter in the brain, L-Glutamic acid directly contributes to glutamate receptor activation. Binding to these receptors can enhance synaptic plasticity and neuronal communication, potentially upregulating ERICH4 activity in related pathways. | ||||||
N-Methyl-D-Aspartic acid (NMDA) | 6384-92-5 | sc-200458 sc-200458A | 50 mg 250 mg | $109.00 $369.00 | 2 | |
NMDA (N-Methyl-D-aspartic acid) selectively activates NMDA receptors, a type of glutamate receptor, leading to calcium influx and subsequent signaling cascades that could enhance the functional activity of ERICH4 by affecting associated glutamatergic pathways. | ||||||
Kainic acid | 487-79-6 | sc-200454 sc-200454A sc-200454B sc-200454C sc-200454D | 5 mg 25 mg 100 mg 1 g 5 g | $87.00 $370.00 $1377.00 $7803.00 $24970.00 | 12 | |
Kainic acid acts as an agonist at kainate receptors (a subtype of glutamate receptors), which can modulate synaptic transmission and possibly enhance the activity of proteins related to glutamate signaling, such as ERICH4. | ||||||
D-Serine | 312-84-5 | sc-391671 sc-391671A sc-391671B | 5 g 25 g 100 g | $43.00 $128.00 $204.00 | ||
D-Serine serves as a co-agonist along with glutamate for the NMDA receptor. Its presence can enhance NMDA receptor activity, potentially affecting ERICH4 activity by modifying glutamatergic neurotransmission. | ||||||
S-Nitrosoglutathione (GSNO) | 57564-91-7 | sc-200349 sc-200349B sc-200349A sc-200349C | 10 mg 25 mg 50 mg 100 mg | $87.00 $210.00 $346.00 $449.00 | 15 | |
S-Nitrosoglutathione can release nitric oxide, which acts as a neuromodulator and can influence glutamatergic signaling. This action may indirectly enhance ERICH4 activity by modulating the neurotransmission processes that ERICH4 is associated with. | ||||||
Cyclothiazide | 2259-96-3 | sc-202560 sc-202560A | 10 mg 50 mg | $107.00 $227.00 | 3 | |
Cyclothiazide acts as a positive allosteric modulator of AMPA receptors, preventing desensitization and thus potentiating the action of glutamate. This potentiation could lead to increased ERICH4 functional activity in the context of glutamatergic neurotransmission. | ||||||
Aniracetam | 72432-10-1 | sc-203514 sc-203514A | 50 mg 250 mg | $115.00 $456.00 | ||
Aniracetam is known to modulate AMPA receptors and can enhance synaptic transmission in the central nervous system. Through this modulation, it could enhance ERICH4 activity if ERICH4 is functionally connected to AMPA receptor pathways. | ||||||
Fenobam | 57653-26-6 | sc-202608 sc-202608A | 5 mg 25 mg | $86.00 $306.00 | ||
Fenobam is an mGluR5 antagonist, and by inhibiting this metabotropic receptor, it could influence the glutamatergic signaling balance, which could indirectly enhance the activity of proteins like ERICH4 involved in these pathways. | ||||||